Graft Versus Host Disease (GVHD)

**Prevention**
- **BMT304**
  - Phase II
  - Obinutuzumab in Prevention of cGVHD After Allogeneic Peripheral Blood Stem Cell Transplant
  - PI: Miklos Dana Farber

**Chronic**
- **BMT350-EXT**
  - Extended Treatment & Follow-up of Subjects Treated w/ Belumosudil in Study KD025-208 or KD025-213
  - PI: Arai Kadmon Corporation, LLC

- **BMT363**
  - Early Detection of Bronchiolitis Obliterans Syndrome in Survivors of HCT w/ Handheld Spirometry
  - PI: Hsu Fred Hutch

- **BMT374**
  - Phase II
  - Axitinib in Recurrent/Refractory Active Chronic GVHD Who Have Received >=2 Lines of Systemic Therapy
  - PI: Arai Sponsor; Syndax Pharmaceuticals, Inc.

**Acute**
- **BMT380**
  - Phase III Randomized Double-Blind Placebo-Controlled Multicenter Study of Ilozumab in Combination w/ Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
  - PI: Johnston Equilibrium, Inc.

**Steroid Refractory GI-aGVHD**
- **BMT344**
  - Phase III Alpha L-Antitrypsin +/- Corticosteroids in High Risk Acute GVHD After Allogeneic HSCT
  - PI: Shiraz Stanford

- **BMT379**
  - Randomized, Double-Blind Trial to Evaluate the Safety and Efficacy of Apraglutide in Subjects with Grade II to IV Steroid Refractory GI aGVHD
  - PI: Arai VectivBio AG